Company

Corcept Therapeutics Incorporated

Headquarters: Menlo Park, CA, United States

Founded: May 13, 1998

Employees: 238

CEO: Dr. Joseph K. Belanoff

NASDAQ: CORT +2.66%

Market Cap

$2.50 Billion

USD as of Jan. 1, 2024

Market Cap History

Corcept Therapeutics Incorporated market capitalization over time

Evolution of Corcept Therapeutics Incorporated market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Corcept Therapeutics Incorporated

Detailed Description

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.

Top 1-year algo backtest: +284.14%

$10,000 in April 2023 would now be $38,414 by following this algorithm daily at market close.

Boost your stocks returns with Disfold AI... Now!

Try Disfold AI for FREE

Stocks & Indices

Corcept Therapeutics Incorporated has the following listings and related stock indices.


Stock: NASDAQ: CORT wb_incandescent

Stock: FSX: HTD wb_incandescent

Product & Services

Pharmaceutics

Key People

Joseph K. Belanoff (CEO, President, & Director) Robert S. Fishman (Chief medical officer)

Details

Headquarters:

149 Commonwealth Drive

Menlo Park, CA 94025

United States

Phone: 650 327 3270

Fax: 650 327 3218